Target-based drug discovery: is something wrong?

[1]  H. Paulson,et al.  RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia , 2004, Nature Medicine.

[2]  G. Boog.  Obstetrical complications and subsequent schizophrenia in adolescent and young adult offsprings: is there a relationship? , 2004, European journal of obstetrics, gynecology, and reproductive biology.

[3]  F. Natt,et al.  siRNA relieves chronic neuropathic pain. , 2004, Nucleic acids research.

[4]  J. Brotchi,et al.  Recombinant AAV‐mediated gene delivery to the central nervous system , 2004, The journal of gene medicine.

[5]  B. Hoffer,et al.  Short interfering RNAs (siRNAs) for reducing dopaminergic phenotypic markers , 2003, Journal of Neuroscience Methods.

[6]  G. Superti-Furga,et al.  Rediscovering the sweet spot in drug discovery. , 2003, Drug discovery today.

[7]  J. Drews.  Stategic trends in the drug industry. , 2003, Drug discovery today.

[8]  Li Di,et al.  Pharmaceutical profiling in drug discovery. , 2003, Drug discovery today.

[9]  M. Véniant,et al.  Leptin: from animals to humans. , 2003, Current pharmaceutical design.

[10]  T. Peakman,et al.  Delivering the power of discovery in large pharmaceutical organizations. , 2003, Drug discovery today.

[11]  Sumit K Chanda,et al.  Fulfilling the promise: drug discovery in the post-genomic era. , 2003, Drug discovery today.

[12]  E. Paykel,et al.  The role of noradrenaline and selective noradrenaline reuptake inhibition in depression , 2002, European Neuropsychopharmacology.

[13]  James D. Thompson.  Applications of antisense and siRNAs during preclinical drug development. , 2002, Drug discovery today.

[14]  R. Duman,et al.  Pathophysiology of depression: the concept of synaptic plasticity , 2002, European Psychiatry.

[15]  M. Murcko,et al.  Transforming the genome to drug discovery. , 2002, Drug discovery today.

[16]  F. Barone,et al.  Pharmacological interventions for stroke: failures and future , 2002, Expert opinion on investigational drugs.

[17]  Jeffrey S Handen,et al.  The industrialization of drug discovery. , 2002, Drug discovery today.

[18]  Ronald S Duman,et al.  Regulation of Adult Neurogenesis by Antidepressant Treatment , 2001, Neuropsychopharmacology.

[19]  J. Mullins,et al.  Conditional transgenic technologies. , 2001, The Journal of endocrinology.

[20]  D. Szymkowski.  Too many targets, not enough target validation. , 2001, Drug discovery today.

[21]  J. Drews.  Drug discovery: a historical perspective. , 2000, Science.

[22]  Stroke Therapy Academic Industry Roundtable.  Recommendations for standards regarding preclinical neuroprotective and restorative drug development. , 1999, Stroke.

[23]  R. Stacey.  Strategic Management and Organisational Dynamics: The Challenge of Complexity , 1999 .

[24]  J. Drews.  Genomic sciences and the medicine of tomorrow , 1996, Nature Biotechnology.

[25]  Jürgen Drews,et al.  Innovation Deficit in the Pharmaceutical Industry , 1996 .

[26]  Walter H. Moos,et al.  Diagnosing the decline of major pharmaceutical research laboratories: A prescription for drug companies , 1995 .

[27]  Richard Whittington,et al.  Exploring Corporate Strategy , 1988 .

[28]  Innovation OR Stagnation.  Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .

[29]  D. Fitzgerald,et al.  Target selection in drug discovery , 2004 .

[30]  M. Lindsay.  Target discovery , 2003, Nature Reviews Drug Discovery.

[31]  Drews.  Drug discovery today - and tomorrow. , 2000, Drug discovery today.

[32]  F. Sams-Dodd.  Phencyclidine in the Social Interaction Test: An Animal Model of Schizophrenia with Face and Predictive Validity , 1999, Reviews in the neurosciences.